93 related articles for article (PubMed ID: 32921395)
1. Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds.
Guo W; Xu Q
J Pharmacol Sci; 2020 Nov; 144(3):139-146. PubMed ID: 32921395
[TBL] [Abstract][Full Text] [Related]
2. Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes.
Martinelli S; Torreri P; Tinti M; Stella L; Bocchinfuso G; Flex E; Grottesi A; Ceccarini M; Palleschi A; Cesareni G; Castagnoli L; Petrucci TC; Gelb BD; Tartaglia M
Hum Mol Genet; 2008 Jul; 17(13):2018-29. PubMed ID: 18372317
[TBL] [Abstract][Full Text] [Related]
3. LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity.
Tajan M; Batut A; Cadoudal T; Deleruyelle S; Le Gonidec S; Saint Laurent C; Vomscheid M; Wanecq E; Tréguer K; De Rocca Serra-Nédélec A; Vinel C; Marques MA; Pozzo J; Kunduzova O; Salles JP; Tauber M; Raynal P; Cavé H; Edouard T; Valet P; Yart A
Proc Natl Acad Sci U S A; 2014 Oct; 111(42):E4494-503. PubMed ID: 25288766
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia.
Zhang W; Chan RJ; Chen H; Yang Z; He Y; Zhang X; Luo Y; Yin F; Moh A; Miller LC; Payne RM; Zhang ZY; Fu XY; Shou W
J Biol Chem; 2009 Aug; 284(33):22353-22363. PubMed ID: 19509418
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
6. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
7. Noonan Syndrome-Associated SHP2 Dephosphorylates GluN2B to Regulate NMDA Receptor Function.
Levy AD; Xiao X; Shaw JE; Sudarsana Devi SP; Katrancha SM; Bennett AM; Greer CA; Howe JR; Machida K; Koleske AJ
Cell Rep; 2018 Aug; 24(6):1523-1535. PubMed ID: 30089263
[TBL] [Abstract][Full Text] [Related]
8. Melanoma and LEOPARD Syndrome: Understanding the Role of PTPN11 Mutations in Melanomagenesis.
Palacios-Diaz RD; Pozuelo-Ruiz M; De Unamuno-Bustos B; Llavador-Ros M; Botella-Estrada R
Acta Derm Venereol; 2024 Jan; 104():adv14720. PubMed ID: 38189222
[No Abstract] [Full Text] [Related]
9. SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
Sodir NM; Pathria G; Adamkewicz JI; Kelley EH; Sudhamsu J; Merchant M; Chiarle R; Maddalo D
Cancer Discov; 2023 Nov; 13(11):2339-2355. PubMed ID: 37682219
[TBL] [Abstract][Full Text] [Related]
10. Protein Tyrosine Phosphatase SHP-2 (PTPN11) in Hematopoiesis and Leukemogenesis.
Liu X; Qu CK
J Signal Transduct; 2011; 2011():195239. PubMed ID: 21799948
[TBL] [Abstract][Full Text] [Related]
11. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Wu J; Zhang H; Zhao G; Wang R
Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
[TBL] [Abstract][Full Text] [Related]
13. SHP2 promotes proliferation of breast cancer cells through regulating Cyclin D1 stability
Yuan Y; Fan Y; Gao Z; Sun X; Zhang H; Wang Z; Cui Y; Song W; Wang Z; Zhang F; Niu R
Cancer Biol Med; 2020 Aug; 17(3):707-725. PubMed ID: 32944401
[No Abstract] [Full Text] [Related]
14. Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities - A comprehensive review.
Tripathi RKP; Ayyannan SR
Chem Biol Drug Des; 2021 Mar; 97(3):721-773. PubMed ID: 33191603
[TBL] [Abstract][Full Text] [Related]
15. An allosteric interaction controls the activation mechanism of SHP2 tyrosine phosphatase.
Anselmi M; Hub JS
Sci Rep; 2020 Oct; 10(1):18530. PubMed ID: 33116231
[TBL] [Abstract][Full Text] [Related]
16. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
[TBL] [Abstract][Full Text] [Related]
17. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Kerr DL; Haderk F; Bivona TG
Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
[TBL] [Abstract][Full Text] [Related]
18. Targeting SHP2 as a therapeutic strategy for inflammatory diseases.
Liu Y; Yang X; Wang Y; Yang Y; Sun D; Li H; Chen L
Eur J Med Chem; 2021 Mar; 214():113264. PubMed ID: 33582386
[TBL] [Abstract][Full Text] [Related]
19. SHP2 Nuclear/Cytoplasmic Trafficking in Granulosa Cells Is Essential for Oocyte Meiotic Resumption and Maturation.
Idrees M; Kumar V; Joo MD; Ali N; Lee KW; Kong IK
Front Cell Dev Biol; 2020; 8():611503. PubMed ID: 33553147
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
